- Home
- HCKT vs KALV Comparison
HCKT vs KALV Comparison
Compare HCKT & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCKT
- KALV
- Stock Information
- Founded
- HCKT 1991
- KALV N/A
- Country
- HCKT United States
- KALV United States
- Employees
- HCKT N/A
- KALV N/A
- Industry
- HCKT Professional Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- HCKT Consumer Discretionary
- KALV Health Care
- Exchange
- HCKT Nasdaq
- KALV Nasdaq
- Market Cap
- HCKT 678.4M
- KALV 642.3M
- IPO Year
- HCKT 1998
- KALV N/A
- Fundamental
- Price
- HCKT $23.50
- KALV $12.15
- Analyst Decision
- HCKT Strong Buy
- KALV Strong Buy
- Analyst Count
- HCKT 3
- KALV 8
- Target Price
- HCKT $31.33
- KALV $24.83
- AVG Volume (30 Days)
- HCKT 166.9K
- KALV 781.4K
- Earning Date
- HCKT 08-05-2025
- KALV 07-10-2025
- Dividend Yield
- HCKT 2.06%
- KALV N/A
- EPS Growth
- HCKT N/A
- KALV N/A
- EPS
- HCKT 0.84
- KALV N/A
- Revenue
- HCKT $307,532,000.00
- KALV N/A
- Revenue This Year
- HCKT $6.06
- KALV N/A
- Revenue Next Year
- HCKT $5.46
- KALV N/A
- P/E Ratio
- HCKT $27.67
- KALV N/A
- Revenue Growth
- HCKT 3.49
- KALV N/A
- 52 Week Low
- HCKT $21.12
- KALV $7.30
- 52 Week High
- HCKT $34.02
- KALV $15.50
- Technical
- Relative Strength Index (RSI)
- HCKT 34.65
- KALV 44.01
- Support Level
- HCKT $24.07
- KALV $11.11
- Resistance Level
- HCKT $24.70
- KALV $13.38
- Average True Range (ATR)
- HCKT 0.45
- KALV 0.77
- MACD
- HCKT -0.06
- KALV -0.17
- Stochastic Oscillator
- HCKT 19.82
- KALV 4.90
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.